Bocom initiated coverage of BeiGene with a Buy rating and $210 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BGNE:
- BeiGene price target raised to $254 from $236 at TD Cowen
- New Risks Emerge for BeiGene: Investors Alerted to Material Updates in Financial Disclosures
- BeiGene reports Q1 EPS ($2.41), consensus ($2.54)
- BeiGene price target raised to $236 from $235 at TD Cowen
- BeiGene receives European Commission approval for tislelizumab